Protein kinase A-dependent phosphorylation of Dock180 at serine residue 1250 is important for glioma growth and invasion stimulated by platelet derived-growth factor receptor α

Neuro Oncol. 2015 Jun;17(6):832-42. doi: 10.1093/neuonc/nou323. Epub 2014 Dec 2.

Abstract

Background: Dedicator of cytokinesis 1 (Dock1 or Dock180), a bipartite guanine nucleotide exchange factor for Rac1, plays critical roles in receptor tyrosine kinase-stimulated cancer growth and invasion. Dock180 activity is required in cell migration cancer tumorigenesis promoted by platelet derived growth factor receptor (PDGFR) and epidermal growth factor receptor.

Methods: To demonstrate whether PDGFRα promotes tumor malignant behavior through protein kinase A (PKA)-dependent serine phosphorylation of Dock180, we performed cell proliferation, viability, migration, immunoprecipitation, immunoblotting, colony formation, and in vivo tumorigenesis assays using established and short-term explant cultures of glioblastoma cell lines.

Results: Stimulation of PDGFRα results in phosphorylation of Dock180 at serine residue 1250 (S1250), whereas PKA inhibitors H-89 and KT5720 oppose this phosphorylation. S1250 locates within the Rac1-binding Dock homology region 2 domain of Dock180, and its phosphorylation activates Rac1, p-Akt, and phosphorylated extracellular signal-regulated kinase 1/2, while promoting cell migration, in vitro. By expressing RNA interference (RNAi)-resistant wild-type Dock180, but not mutant Dock180 S1250L, we were able to rescue PDGFRα-associated signaling and biological activities in cultured glioblastoma multiforme (GBM) cells that had been treated with RNAi for suppression of endogenous Dock180. In addition, expression of the same RNAi-resistant Dock180 rescued an invasive phenotype of GBM cells following intracranial engraftment in immunocompromised mice.

Conclusion: These data describe an important mechanism by which PDGFRα promotes glioma malignant phenotypes through PKA-dependent serine phosphorylation of Dock180, and the data thereby support targeting the PDGFRα-PKA-Dock180-Rac1 axis for treating GBM with molecular profiles indicating PDGFRα signaling dependency.

Keywords: Dock180; PDGFRα; PKA; glioblastomas; phosphorylation.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Brain Neoplasms / metabolism*
  • Carbazoles / pharmacology
  • Cell Line, Tumor
  • Cell Movement
  • Cell Proliferation
  • Cell Survival
  • Cyclic AMP-Dependent Protein Kinases / antagonists & inhibitors
  • Cyclic AMP-Dependent Protein Kinases / metabolism*
  • Female
  • Glioblastoma / metabolism*
  • HEK293 Cells
  • Humans
  • Isoquinolines / pharmacology
  • Mice
  • Phosphorylation
  • Platelet-Derived Growth Factor / pharmacology
  • Protein Kinase Inhibitors / pharmacology
  • Pyrroles / pharmacology
  • Receptor, Platelet-Derived Growth Factor alpha / agonists
  • Receptor, Platelet-Derived Growth Factor alpha / metabolism*
  • Signal Transduction
  • Sulfonamides / pharmacology
  • rac GTP-Binding Proteins / metabolism*

Substances

  • Carbazoles
  • DOCK1 protein, human
  • Isoquinolines
  • Platelet-Derived Growth Factor
  • Protein Kinase Inhibitors
  • Pyrroles
  • Sulfonamides
  • platelet-derived growth factor A
  • KT 5720
  • Receptor, Platelet-Derived Growth Factor alpha
  • Cyclic AMP-Dependent Protein Kinases
  • rac GTP-Binding Proteins
  • N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide